Targeting LRRK2 mutations in Parkinson's disease

Robert K Leśniak; Robert Jeremy Nichols; Mark Smith; Thomas J Montine

doi:10.4155/fmc-2022-0102

Targeting LRRK2 mutations in Parkinson's disease

Future Med Chem. 2022 Aug;14(16):1167-1170. doi: 10.4155/fmc-2022-0102. Epub 2022 Jun 22.

Authors

Robert K Leśniak^{1

2}, Robert Jeremy Nichols², Mark Smith¹, Thomas J Montine²

Affiliations

¹ Medicinal Chemistry Knowledge Center, Sarafan ChEM-H, Stanford University, Stanford, CA 94305, USA.
² Department of Pathology, 300 Pasteur Drive, Stanford University, Stanford, CA 94305, USA.

PMID: 35730403
DOI: 10.4155/fmc-2022-0102

No abstract available

Keywords: computational chemistry and molecular modeling; drug design; drug discovery; inflammation therapeutics; neurological therapeutics; pharmacokinetics/pharmacodynamics; rare diseases.

Publication types

Editorial

MeSH terms

Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
Mutation
Parkinson Disease* / genetics

Substances

LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2